Fig. 1 summarizes the association between the four CHRNA5-A3-B4 variants and verified smoking abstinence at the different time points assessed among the participants who received the active nicotine gum treatment (Study 1, Fig.1A), the active bupropion treatment (Study 2, Fig.1B), any active pharmacological treatment (Study 1 and 2, Fig.1C), or the placebo treatment (Study 1 and 2, Fig.1D). For additive models please see Supplementary Fig.S1). Some notable impacts of the variants on abstinence are highlighted below.
